Skip to main content

Market Overview

No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a thinly traded micro-cap biotech, plummeted Tuesday morning.

What Happened

Aldeyra, which focuses on therapies for immune-mediated diseases, reported its Phase 3 trial dubbed SOLACE that evaluated its reproxalap, code-named ADX-102 (a topical ophthalmic solution) in non-infectious anterior uveitis did not meet both the primary and secondary endpoints.

Anterior uveitis is an inflammation of the middle layer of the eye.

The company clarified the failure of the study was due to high rates of disease resolution in vehicle-treated patients, but said the activity of reproxalap was consistently greater than that of vehicle.

Reproxalap is also being evaluated in separate late-stage studies in allergic conjunctivitis as well as dry eye disease. In a Phase 3 study for the former indication and in a Phase 2a study for the latter indication, the pipeline asset showed highly statistically significant immune-modulating activity.

What's Next

Aldeyra said it looks forward to aggressively prioritize advancement of high-valve ocular programs in dry eye disease, allergic conjunctivitis and proliferative vitreoretinopathy.

Aldeyra shares traded lower by 25.9% to $5.25 in Tuesday's pre-market session.

Related Links:

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale

FDA Type A Meetings: What You Need To Know


Related Articles (ALDX)

View Comments and Join the Discussion!

Posted-In: Biotech News Small Cap General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at